JP4216196B2 - Ｎｐｙアンタゴニストとしてのキノリン誘導体 - Google Patents

Ｎｐｙアンタゴニストとしてのキノリン誘導体 Download PDF

Info

Publication number
JP4216196B2
JP4216196B2 JP2003565479A JP2003565479A JP4216196B2 JP 4216196 B2 JP4216196 B2 JP 4216196B2 JP 2003565479 A JP2003565479 A JP 2003565479A JP 2003565479 A JP2003565479 A JP 2003565479A JP 4216196 B2 JP4216196 B2 JP 4216196B2
Authority
JP
Japan
Prior art keywords
methyl
pyrrolidin
quinolin
alkyl
iodo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003565479A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523901A (ja
JP2005523901A5 (cg-RX-API-DMAC7.html
Inventor
マタイ，パトリツィオ
ミュラー，ヴェルナー
ニダール，ヴェルナー
ネッテコフェン，マサイアス・ハインリヒ
プフリーガー，フィリッペ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2005523901A publication Critical patent/JP2005523901A/ja
Publication of JP2005523901A5 publication Critical patent/JP2005523901A5/ja
Application granted granted Critical
Publication of JP4216196B2 publication Critical patent/JP4216196B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2003565479A 2002-02-04 2003-01-27 Ｎｐｙアンタゴニストとしてのキノリン誘導体 Expired - Fee Related JP4216196B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02001967 2002-02-04
PCT/EP2003/000777 WO2003066055A1 (en) 2002-02-04 2003-01-27 Quinoline derivatives as npy antagonists

Publications (3)

Publication Number Publication Date
JP2005523901A JP2005523901A (ja) 2005-08-11
JP2005523901A5 JP2005523901A5 (cg-RX-API-DMAC7.html) 2005-12-22
JP4216196B2 true JP4216196B2 (ja) 2009-01-28

Family

ID=27635782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003565479A Expired - Fee Related JP4216196B2 (ja) 2002-02-04 2003-01-27 Ｎｐｙアンタゴニストとしてのキノリン誘導体

Country Status (19)

Country Link
US (1) US6696467B2 (cg-RX-API-DMAC7.html)
EP (1) EP1474145B1 (cg-RX-API-DMAC7.html)
JP (1) JP4216196B2 (cg-RX-API-DMAC7.html)
KR (1) KR100659428B1 (cg-RX-API-DMAC7.html)
CN (1) CN100383124C (cg-RX-API-DMAC7.html)
AR (1) AR038249A1 (cg-RX-API-DMAC7.html)
AT (1) ATE392897T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003205679B2 (cg-RX-API-DMAC7.html)
BR (1) BR0307441A (cg-RX-API-DMAC7.html)
CA (1) CA2473181A1 (cg-RX-API-DMAC7.html)
DE (1) DE60320529T2 (cg-RX-API-DMAC7.html)
ES (1) ES2304498T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04007502A (cg-RX-API-DMAC7.html)
PE (1) PE20040120A1 (cg-RX-API-DMAC7.html)
PL (1) PL372295A1 (cg-RX-API-DMAC7.html)
RU (1) RU2298002C2 (cg-RX-API-DMAC7.html)
TW (1) TW200400032A (cg-RX-API-DMAC7.html)
UY (1) UY27646A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003066055A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
JP2004110367A (ja) * 2002-09-18 2004-04-08 Hitachi Ltd 記憶装置システムの制御方法、記憶制御装置、および記憶装置システム
US7317025B2 (en) * 2003-09-24 2008-01-08 Johnson & Johnson Pharmaceutical Research & Development, Llc Non-peptidic NPY Y2 receptor inhibitors
ES2369835T3 (es) 2003-11-19 2011-12-07 Array Biopharma, Inc. Inhibidores bicíclicos de mek y métodos de síntesis de los mismos.
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
WO2007038865A1 (en) * 2005-10-05 2007-04-12 Merck Frosst Canada Ltd. Substituted quinolines as inhibitors of leukotriene biosynthesis
RU2314295C2 (ru) * 2006-03-01 2008-01-10 Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" 2-гетарилзамещенные 1,3-трополона, способ их получения (варианты) и фармацевтическая композиция антимикробного действия
WO2008141077A1 (en) * 2007-05-10 2008-11-20 Janssen Pharmaceutica N.V. Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives
PT2182950T (pt) * 2007-05-17 2017-09-11 Helperby Therapeutics Ltd Uso de compostos 4-(pirrolidin-1-il)quinolina para eliminação de microrganismos clinicamente latentes
WO2010056865A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Quinoline derivatives as ion channel modulators
PT2448582T (pt) * 2009-06-29 2017-07-10 Agios Pharmaceuticals Inc Compostos e composições terapêuticas
MX337042B (es) * 2010-12-03 2016-02-10 Dow Agrosciences Llc Procesos para la preparacion de enaminas.
US8865741B2 (en) 2011-02-18 2014-10-21 Asana Biosciences, Llc Aminoindane compounds and use thereof in treating pain
BR112013033316A2 (pt) 2011-06-24 2017-01-31 Amgen Inc antagonista de trpm8 e seu uso em tratamentos
AU2012272898A1 (en) 2011-06-24 2013-04-11 Amgen Inc. TRPM8 antagonists and their use in treatments
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9044482B2 (en) 2012-08-15 2015-06-02 Asana Biosciences, Llc Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
WO2015116904A1 (en) 2014-02-03 2015-08-06 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
KR102324042B1 (ko) 2016-07-14 2021-11-09 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 및 그의 용도
TWI774767B (zh) 2017-05-12 2022-08-21 瑞士商多蒂孔股份有限公司 茚烷衍生物及其在有機電子產品的用途
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
BR112020001246A2 (pt) 2017-07-24 2020-07-21 Vitae Pharmaceuticals, Llc inibidores de rory
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
JP7269917B2 (ja) * 2017-08-17 2023-05-09 イケナ オンコロジー， インコーポレイテッド Ａｈｒ阻害剤およびその使用
PL3740475T3 (pl) * 2018-01-17 2022-08-16 Crinetics Pharmaceuticals, Inc. Sposób wytwarzania modulatorów somatostatyny
RU2702648C1 (ru) * 2019-07-11 2019-10-09 федеральное государственное автономное образовательное учреждение высшего образования «Южный федеральный университет» 5,7-Ди(трет-бутил)-2-(4,7-дихлор-8-метил-5-нитрохинолин-2-ил)-4-нитро-1,3-трополон, обладающий цитотоксической активностью
PE20231850A1 (es) 2020-09-09 2023-11-21 Crinetics Pharmaceuticals Inc Formulaciones de un modulador de somatostatina

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035367A (en) * 1974-09-09 1977-07-12 Sandoz, Inc. Hydroxyalkyl-substituted-amino-quinolines
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
CA2133620A1 (en) * 1993-10-28 1995-04-29 Werner Hofheinz Aminoquinoline derivatives
RU2161967C2 (ru) * 1994-08-18 2001-01-20 Дзе Проктер Энд Гэмбл Компани Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора
US5552411A (en) * 1995-05-26 1996-09-03 Warner-Lambert Company Sulfonylquinolines as central nervous system and cardiovascular agents
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
KR20010079636A (ko) 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물
WO2000009122A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
DE10064105A1 (de) * 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
CA2446324A1 (en) * 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor

Also Published As

Publication number Publication date
AU2003205679B2 (en) 2006-06-29
TW200400032A (en) 2004-01-01
AU2003205679A1 (en) 2003-09-02
JP2005523901A (ja) 2005-08-11
ATE392897T1 (de) 2008-05-15
AR038249A1 (es) 2005-01-05
BR0307441A (pt) 2005-01-04
US20030153553A1 (en) 2003-08-14
PL372295A1 (en) 2005-07-11
CN100383124C (zh) 2008-04-23
US6696467B2 (en) 2004-02-24
UY27646A1 (es) 2003-08-29
RU2004126936A (ru) 2005-10-10
CA2473181A1 (en) 2003-08-14
ES2304498T3 (es) 2008-10-16
PE20040120A1 (es) 2004-03-06
EP1474145B1 (en) 2008-04-23
DE60320529T2 (de) 2009-06-10
CN1627945A (zh) 2005-06-15
KR100659428B1 (ko) 2006-12-19
MXPA04007502A (es) 2004-11-10
RU2298002C2 (ru) 2007-04-27
EP1474145A1 (en) 2004-11-10
DE60320529D1 (de) 2008-06-05
WO2003066055A1 (en) 2003-08-14
KR20040081484A (ko) 2004-09-21

Similar Documents

Publication Publication Date Title
JP4216196B2 (ja) Ｎｐｙアンタゴニストとしてのキノリン誘導体
JP3715280B2 (ja) ニューロペプチドｙレセプターのリガンドとしてのキノリン誘導体
JP4187652B2 (ja) ニューロペプチドｙアンタゴニストとしてのキノリン誘導体
JP3095521B2 (ja) ピペラジン誘導体
JP2004508357A (ja) キノリンおよびキナゾリン誘導体
WO2007063925A1 (ja) ２－アミノベンズアミド誘導体
JP5487100B2 (ja) アデノシンａ３受容体リガンドとしてのトリアゾロ［１，５−ａ］キノリン
JP5069119B2 (ja) 血管内皮成長因子（ｖｅｇｆ）受容体キナーゼインヒビターとしてのニコチンアミドピリジンウレア
RU2296757C2 (ru) Производные хиназолина
JP2005139106A (ja) ベンゾフラン誘導体

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081104

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081105

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111114

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees